Global Anti-Cathepsin B Market to surpass US$ 208.19 million by 2027, Says Coherent Market Insights (CMI)

SEATTLE–(BUSINESS WIRE)–#AntiCathepsinB–According to Coherent Market Insights, the global anti-cathepsin B market is estimated to be valued at US$ 166.52 million in 2020 and is expected to exhibit a CAGR of 2.8% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Anti-Cathepsin B Market:

The increasing number of potential research candidates of anti-cathespin B in the market is also expected to drive growth of the anti-cathepsin B market over the forecast period. For example, Virobay Inc. claimed that 12 novel haloalkyl amino acid amide derivatives are useful in treating diseases mediated by cathepsin B, K, L, F, and S which included asthma, arthritis, atherosclerosis, chronic obstructive pulmonary disease, multiple sclerosis, or psoriasis. All the twelve compounds exhibited inhibitory activity of cathepsin B, L, K, F, and S. In particular, 10 out of 12 compounds showed potent inhibition to cathepsin S with Ki values of <100 nM. Especially, compound 5 exhibited good selectivity for cathepsin B with a Ki of <100 nM over cathepsin L, K, F, and S.

Furthermore, key players are focused on research and development of anti-cathepsin B drugs to make advancements and to increase customer base. For instance, according to data published by the National Center for Biotechnology Information (NCBI) in January 2016, Cathepsin B inhibitors may also help potentiate current chemotherapies. Since cathepsin B was reported to protect tumors against cell death induced by chemotherapeutic agents such as Taxol, combination of Taxol and cathepsin inhibitors in vivo, it significantly enhanced efficacy against primary and metastatic tumors.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4169

Key Market Takeaways:

(Read more…)

The global anti-cathepsin B market is expected to exhibit a CAGR of 2.8% during the forecast period (2020-2027) owing to increasing funding and investments. For instance, in July 2014, Virobay, Inc., a clinical stage pharmaceutical company with a platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune disease and fibrosis. They announced the closing of an expanded Series B second tranche financing of US$ 8.0 million. Including this recent US$ 8 million investment, Virobay has raised an aggregate of US$ 18 million in two tranches of the Series B financing.

North America anti-cathepsin B market is expected to grow over the forecast period owing to the rising prevalence of conditions such as cancer or traumatic brain injury. For instance, according to data published by the Centers of Disease Control and Prevention in 2017, traumatic brain injury (TBI) is a major cause of death and disability in the U.S. TBIs contribute to about 30% of all injury deaths. 153 people in the U.S. die per day, from injuries that include TBI.

Competitive Landscape:

Key players operating in the global anti-cathepsin B market are Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, BOC Sciences, AG Scientific, Virobay Inc. and Abcam Plc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4169

Market Segmentation:

• Global Anti-Cathespin B Market, By Type:
  • Primary Antibodies
  • Proteins and Peptides
  • Lysates

• Global Anti-Cathespin B Market, By Research Application:
  • Cancer
  • Traumatic Brain Injury
  • Ebola Infection
  • Fertility Treatment
  • Others

• Global Anti-Cathespin B Market, By Technique:
  • Immunohistochemistry
  • Immunofluorescence
  • Western Blotting
  • ELISA
  • Flow Cytometry
  • Others

• Global Anti-Cathespin B Market, By End User:
  • Pharmaceutical Companies
  • Academic and Research Institutes

• Global Anti-Cathespin B Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Europe
    • By Country:
      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

Phone:
US: +1-206-701-6702

UK: +44-020-8133-4027

Japan: +81-050-5539-1737

India: +91-848-285-0837

Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter